Some WHO-approved malaria drugs fall short: study

July 10, 2012

Up to eight percent of malaria drugs approved by the World Health Organization or other regulators do not contain the right dose and may fuel resistance, researchers said Tuesday.

Two studies in published in Research and Reports in suggested manufacturing problems, rather than counterfeiting, may be to blame for these substandard drugs in low and around the world.

Poorly made or fake medications are a major problem worldwide, particularly as signs emerge of growing resistance to artemisinin, the frontline treatment for malaria, a disease the UN's (WHO) says killed 655,000 people in 2010.

One study sampled 104 artemisinin-based medicines from pharmacies in Ghana and Nigeria that were offered under the Affordable Medicines Facility by the Global Fund to Fight AIDS, designed to boost access to the best treatments.

Eight were found to be significantly under-dosed in artemisinin, or had less than 75 percent of the main component of the drug, the study authors said.

"Why am I pretty sure that these are not fakes?" asked Roger Bate, lead author and resident scholar at the American Enterprise Institute.

"The reason is they have well over 50 percent of the active ingredient but under 75 percent," he said, adding that most counterfeits have very little or no in them.

A separate study that spanned 2,652 essential drugs -- including medicines for malaria, tuberculosis and bacterial infections -- found that the failure rate among WHO-approved products was 6.8 percent.

The samples came from 11 sites in Africa, three Indian cities, as well as Sao Paulo, Moscow, Bangkok, Istanbul and Beijing.

The highest failure rate -- 17.65 percent -- was seen among Chinese-made products approved by the WHO, said the study.

Researchers said the WHO has launched an investigation.

Explore further: Fake malaria drugs a growing problem: experts

Related Stories

Fake malaria drugs a growing problem: experts

December 5, 2011
Fake or poor quality malaria drugs are boosting resistance in parts of southeast Asia, a problem that is likely to worsen unless tighter regulations are adopted, US experts said Monday.

Fake malaria drugs threaten crisis in Africa

January 17, 2012
(Medical Xpress) -- The emergence of fake and poor quality anti-malarial drugs could dash hopes of controlling malaria in Africa, warn experts writing in the Malaria Journal. Millions of lives could be put at risk unless ...

Study finds early signs of malaria drug resistance in Africa

April 27, 2012
Africa's deadliest malaria parasite has shown resistance in lab tests to one of the most powerful drugs on the market -- a warning of possible resistance to follow in patients, scientists said Friday.

WHO hopeful drug-resistant malaria can be contained

April 24, 2012
The World Health Organisation said Tuesday it was optimistic drug-resistant malaria that has emerged along Thailand's borders with Cambodia and Myanmar could be contained within the region.

Recommended for you

Fighting opioid addiction in primary care—new study shows it's possible

October 18, 2017
For many of the 2 million Americans addicted to opioids, getting good treatment and getting off prescription painkillers or heroin may seem like a far-off dream.

With no morphine, 25 million die in pain each year: report

October 13, 2017
Every year, some 25 million people—one in ten of them children—die in serious pain that could have been alleviated with morphine at just a few cents per dose, researchers said Friday.

Study finds few restrictions on Rx opioids through Medicare

October 9, 2017
Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for ...

Nocebo effect: Does a drug's high price tag cause its own side effects?

October 5, 2017
Pricey drugs may make people more vulnerable to perceiving side effects, a new study suggests—and the phenomenon is not just "in their heads."

Pre-packaged brand version of compounded medication to prevent preterm births costs 5,000 percent more

October 2, 2017
Preventing a preterm birth could cost as little as $200 or as much as $20,000, depending on which one of two medications a doctor orders, according to a new analysis from Harvard Medical School.

Cancer drugs' high prices not justified by cost of development, study contends

September 12, 2017
(HealthDay)— Excusing the sky-high price tags of many new cancer treatments, pharmaceutical companies often blame high research and development (R&D) costs.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.